GeneThera Inc GTHR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.02
- Bid/Ask
- $0.01 / $0.10
- Market Cap
- $35.33
- Volume/Avg
- 4,000 / 9,535
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 2
- Website
- http://genetherainc.com
Valuation
|
Metric
|
GTHR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GTHR
|
|---|---|
Quick Ratio | — |
Current Ratio | — |
Interest Coverage | — |
Quick Ratio
GTHR
Profitability
|
Metric
|
GTHR
|
|---|---|
Return on Assets (Normalized) | −15,593.80% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
GTHR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mbxznnqzv | Vpmr | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hfpgxsbz | Dqqcx | $108.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wspdvmlwy | Wfsczp | $105.3 Bil | |
MRNA
| Moderna Inc | Ytvcdjyw | Khh | $47.0 Bil | |
ARGX
| argenx SE ADR | Mgjdzdq | Hsvk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zbczlpht | Rlqmr | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cypncskq | Kdwyqwq | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pvmjbnhk | Lntgfg | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fyhzgypcyg | Xwmbqn | $12.6 Bil | |
INCY
| Incyte Corp | Zzdgmglf | Lfmpc | $12.0 Bil |